Alnylam (Nasdaq: ALNY
) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases.
Recognizing that "the rise of modern art coincides with the rise of modern capitalism," Burn points out that there might be an affinity "between those who are looking at modern art's beginnings and those of us who are hoping for its end." Here, then, is a glimpse of another radical difference between ALNY
Alnylam (Nasdaq: ALNY
) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular diseases.
- The US Food and Drug Administration has accepted US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc.'s (NASDAQ: ALNY
) New Drug Application for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria, and granted Priority Review for the NDA, the company said.
) said the FDA has accepted its NDA for givosiran, an investigational RNAi therapeutic, granting the application priority review status.
Tickers featured: AAPL, ABT, ALNY
, CSCO, DGX, GENZ, GOOG, IBM, INTC, KMX, LLY, MCK, MON, MSFT, NEM, NVS, SU, TOT, YUM.
) and has been appointed executive vice president and chief financial officer, effective August 13, 2019, the company said.
Arbutus Biopharma (ABUS) announced the sale of part of its royalty interest on future global net sales of ONPATTRO , patisiran, an RNA interference, RNAi, therapeutic currently being sold by Alnylam Pharmaceuticals (ALNY
), to OMERS, the defined benefit pension plan for municipal employees based in the Province of Ontario, Canada.
Tickers featured: ALNY
, AMGN, CADX, CELG, CEPH, CLRT, CRXL, CYTK, DCGN, GHDX, IDEV, ISIS, MGRM, MYGN, NKTR, OMRI, OREX, REGN, SGMO, SNTA.
), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2019 and reviewed recent business highlights.
) has detailed new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) the molecules that mediate RNAi directed to a liver target, the company said.